Max Healthcare Institute Limited reached a 52-week high during trading on June 17, 2025. The share price touched Rs 1,255.10 on the NSE and closed at Rs 1,252.80, gaining 0.48%. This rise shows growing confidence among investors and signals bullish market sentiment. The stock is part of the NIFTY MIDCAP 150 index, marking its relevance in the Indian mid-cap sector.
Investors are tracking Max Healthcare closely due to its strong financial performance. The company has reported consistent revenue and profit growth over the last five quarters. In March 2024, the revenue stood at ₹1,422.90 crore with a net profit of ₹251.54 crore. By March 2025, the revenue had grown to ₹1,909.74 crore and net profit rose to ₹319.00 crore. Earnings per share also improved from 2.59 to 3.28 in the same period. This upward trend shows solid business expansion and good cost control.
Annual results tell a similar story. In 2021, revenue was ₹2,504.67 crore, with a net loss of ₹114.50 crore and a negative EPS of -1.59. But in 2022, profit turned positive with ₹605.05 crore and EPS at 6.25. The next years brought further growth. By 2025, revenue hit ₹7,028.46 crore and net profit was ₹1,075.88 crore. EPS improved to 11.07, showing stronger earnings for shareholders. Book value per share increased steadily from ₹58.37 in 2021 to ₹96.50 in 2025.
Return on equity moved from negative territory in 2021 to 11.46% by 2025, indicating better use of investor capital. The debt-to-equity ratio, which shows how much the company relies on borrowed funds, stayed low and healthy. It moved from 0.16 in 2021 to 0.32 in 2025, suggesting that the company is growing with balanced financial leverage.
The balance sheet shows growth in total assets and reserves, which supports the company’s expansion plans. Total assets and liabilities increased from ₹8,544 crore in March 2021 to ₹15,214 crore in March 2025. Reserves and surplus rose from ₹4,646 crore to ₹8,408 crore in the same period. Share capital also saw a slight rise from ₹965 crore to ₹972 crore, showing gradual capital expansion without dilution.
Key financial ratios back up this strong performance. Basic EPS rose every year, while the price-to-earnings ratio climbed from negative in 2021 to 99.09 in 2025. Although a high P/E may signal that the stock is expensive, it often reflects investor belief in future earnings growth. The debt-to-equity ratio remained under control, which adds to investor trust.
The stock’s performance on June 17 clearly reflects this solid foundation. With consistent growth across revenue, profit, and earnings, Max Healthcare continues to gain investor attention. Market analysts view this as a sign of healthy operations and a strong outlook. As long as the company maintains this path, its stock may continue to attract buyers and remain a key player in the mid-cap space.
Max Healthcare stock is now seen as one of the stronger performers in its category. Its growth, both financial and operational, makes it a company to watch in the coming months.
